Newron Sweden AB is investigating sNN0029, a VEGF165-based therapeutic, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The market for ALS therapies is growing, driven by increasing awareness and the need for effective treatments. Current treatments are limited, primarily focusing on symptom management rather than disease modification. If sNN0029 demonstrates safety and tolerability, it could position Newron as a key player in the ALS market, potentially leading to partnerships or acquisitions. The collaboration with Medtronic for the delivery system enhances the credibility and feasibility of the approach, but the competitive landscape remains challenging with existing therapies and ongoing research into novel agents.